Nanoscope Therapeutics Showcases Optogenetic Therapy Data at ARVO 2026
Event summary
- Nanoscope Therapeutics will present data on its optogenetic therapy platforms at ARVO 2026 and Eyecelerator @ ARVO 2026 in Denver, Colorado.
- Key presentations include three-year RESTORE trial data for MCO-010 in retinitis pigmentosa (RP) and biodistribution studies for MCO-020 in primates.
- The company is preparing to complete its BLA submission for MCO-010 and plans to initiate a Phase 3 trial for Stargardt disease (SD) in 2026.
- Nanoscope has received multiple regulatory designations, including FDA Fast Track, Orphan Drug, and RMAT for RP and SD.
The big picture
Nanoscope Therapeutics is positioning itself as a leader in optogenetic therapies for retinal degenerative diseases. The company's focus on disease-agnostic platforms and its progress toward regulatory approvals highlight its strategic shift from clinical development to commercialization. The broader industry trend toward one-time, in-office treatments for retinal conditions underscores Nanoscope's potential to disrupt the ophthalmology market.
What we're watching
- Regulatory Momentum
- The pace at which Nanoscope completes its BLA submission and secures approval for MCO-010 will determine its commercialization timeline for RP.
- Clinical Validation
- Whether the three-year RESTORE trial data can solidify MCO-010 as a durable and effective treatment for RP, supporting its potential as a standard of care.
- Pipeline Expansion
- How Nanoscope advances its Phase 2 program for geographic atrophy (GA) and other IND-ready programs, including Leber congenital amaurosis (LCA).
Related topics